Congress Begins Shaping A Research Bonanza

Question of the day: Why is basic research, particularly biomedical research, like highways and bridges? Answer: Because Congress loves them both, especially in this election year. 'MIRACULOUS': NIH, under the direction of Harold Varmus, would get an 8.4 percent increase in its budget under President Clinton's proposed plan. For that reason, as much as any other, the spending plan that Congress is now writing for the fiscal year that begins October 1 shapes up as one of the best research-fundin

Written byBruce Agnew
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Question of the day: Why is basic research, particularly biomedical research, like highways and bridges? Answer: Because Congress loves them both, especially in this election year.

Varmus
'MIRACULOUS': NIH, under the direction of Harold Varmus, would get an 8.4 percent increase in its budget under President Clinton's proposed plan.
For that reason, as much as any other, the spending plan that Congress is now writing for the fiscal year that begins October 1 shapes up as one of the best research-funding budgets in decades, and possibly the best ever.

President Bill Clinton set the tone last month, when he sent Congress a fiscal year (FY) 1999 budget that proposed a $2 billion increase, or 3 percent, in overall federal R&D spending. Clinton plans 8 percent jumps for both defense and civilian basic research, a 6 percent increase for civilian R&D, and a 0.3 percent trim in defense R&D that would raise ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies